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Anticoagulation in patients implanted with ventricularassist devices is widely performed with aspirin, hep-arin, and anti–vitamin K therapy. Nonetheless, a vari-able antiplatelet effect of aspirin is well-known in
healthy subjects. Moreover, the efficacy of aspirin may be reduced
in the days after coronary artery bypass grafting surgery.1 Its
efficacy has not been reported during the chronic phase of me-
chanical support with an external ventricular assist device. We
report a resistance to aspirin that did respond to an increased daily
oral intake and that could be observed as long as 6 weeks after
device implantation.
Methods
Patient selection. Fifteen patients were studied prospectively
during 6 weeks after implantation of an external ventricular assist
device (Thoratec Laboratories Corporation, Pleasanton, Calif).
Two patients were female. Median age was 44.3 years, range was
16.6 to 58.6 years. Indications for emergent device implantation
were persistent primary cardiogenic shock complicating acute
myocardial infarction in 7 patients, acute myocarditis in 2 patients,
and end-stage dilated cardiomyopathy in 6 patients. Seven patients
were supported by an intra-aortic balloon pump before device
implantation. Median duration of support was 72 days (range
28-360 days). Mechanical support was biventricular in 10 patients.
Three patients died while on support of sepsis in 1 case,
intracranial hemorrhage in 1 case, and device dysfunction in 1
case.
Surgical technique and anticoagulation protocol. Implanta-
tion was performed by a standard technique. All patients were
implanted under cardiopulmonary bypass and moderate hypother-
mia. Median cardiopulmonary bypass duration was 162 minutes
(range 96-339 minutes). After surgery, anticoagulation was started
within 8 to 12 hours with intravenous heparin to achieve an
anti-Xa activity between 0.3 and 0.4 IU/L. Aspirin was started
after 24 hours with a starting dose of 250 mg daily (except for 1
patient who had a starting dose of 400 mg daily). Aspirin doses
were then adjusted according to in vitro platelet function tests and
depending on clinical and biologic status. Anti–vitamin K therapy
was started after removal of chest drains and extubation to main-
tain the international normalized ratio between 3 and 4. Fresh
blood drawn for platelet function studies was collected once every
week after implantation. A resistance to aspirin therapy was con-
sidered to have occurred when in vitro testing showed a persistent
platelet aggregation in the presence of arachidonic acid despite
daily administration of aspirin.
Results
Figure 1 shows the numbers of patients during follow up after
device implantation with persistent in vitro platelet aggregation in
the presence of arachidonic acid and despite daily aspirin admin-
istration. This was observed in 6 of 15 patients.
An increase in daily aspirin dose up to 500 mg was associated
with disappearance of platelet aggregation in the presence of
arachidonic acid in vitro. Three patients had a recurrence of this
phenomenon, despite this increased daily aspirin intake in 2 cases.
In 3 patients this observation was done from the first week of
treatment after implantation.
Figure 2 shows the mean dose of aspirin administered per day
and its temporal trends after device implantation. Two patients had
an interruption in treatment because of severe bleeding complica-
tions in the third and fourth postoperative weeks (hemothorax and
intracranial bleeding).
Discussion
Aspirin resistance has been reported in patients after coronary
artery bypass grafting and was associated with an increased re-
cruitment of new platelets in the days after surgery.1 After ven-
tricular assist device implantation, we did observe a persistent in
vitro platelet aggregation as late as 6 weeks after implantation and
despite high doses of aspirin (150 mg/d). In healthy subjects a
dose of 100 mg/d is associated with the absence of in vitro platelet
aggregation.2 When flow conditions are changed, however, as in
patients with atherosclerosis, a higher dose of aspirin is necessary
to preserved the absence of thromboxane A2 production by plate-
lets. This mechanism of resistance to aspirin has been associated
with a prothrombotic effect of erythrocytes on platelet reactivity.3
Also, experimentally increased shear stress has been seen to over-
come the effect of intravenous aspirin.4 Finally, increased platelet
activation is also produced by thrombin generation and cytokine
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production (interleukin 6 and 8) independently of thromboxane
production.5 In patients with external ventricular assist device, all
these conditions (increased shear stress, prolonged inflammatory
reaction, prolonged cytokine production, thrombin generation)
combine to induce a persistent platelet activation and resistance to
the antiplatelet effect of aspirin. Although our observation was
expected, we observed as many as 30% of patients with a persis-
tent platelet response to arachidonic acid. However, a higher dose
of aspirin restored the efficacy of aspirin regarding in vitro platelet
aggregation.
Aspirin resistance in the prolonged postoperative course of
patients implanted with external ventricular assist device is fre-
quent and necessitates close monitoring. However, it will respond
to increased oral intake of aspirin up to 500 mg/d.
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Figure 1. Numbers and percentages of patients with persistent in
vitro platelet aggregation in presence of arachidonic acid during
weekly follow-up after implantation.
Figure 2. Temporal trend of daily dose of aspirin administered per
patient after device implantation. Data points represent mean;
error bars represent SEM.
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